Study details
Enrolling now
Platform Trial for Atopic Dermatitis
Novartis Pharmaceuticals
NCT IDNCT06947993ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
224
Study length
about 3.6 years
Ages
18–100
Locations
22 sites in AL, AR, CA +9
What this study is about
Researchers are testing a treatment called GHZ339 and a placebo in adults with moderate to severe atopic dermatitis. The trial will last about 1 year and involve approximately 224 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take GHZ339
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Change from baseline in the Eczema Area and Severity Index (EASI) score at Week 16
Body systems
Dermatology